|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Consideration should be given to official guidance on the appropriate use of antibacterial agents.|
|Rapid review commissioned||07/12/2021|
|Rapid review completed||24/01/2022|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of oritavancin compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|
The HSE has approved reimbursement following confidential price negotiations June 2022.